AEST.MED.INT.HLD.SP.ADR/3 (3FMA) — Cash Flow-to-Debt Ratio
AEST.MED.INT.HLD.SP.ADR/3 (3FMA) has a Cash Flow-to-Debt Ratio of -0.02x as of December 2025, meaning its operating cash flow of €-12.23 Million could theoretically repay 0% of its total liabilities (€554.12 Million) in one year. See free cash flow generation of AEST.MED.INT.HLD.SP.ADR/3 to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
AEST.MED.INT.HLD.SP.ADR/3 Cash Flow-to-Debt Ratio (2021–2025)
Historical debt coverage capacity for AEST.MED.INT.HLD.SP.ADR/3 across 5 annual periods. Also explore how fast is AEST.MED.INT.HLD.SP.ADR/3 growing its equity to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for AEST.MED.INT.HLD.SP.ADR/3 (2021–2025)
Year-by-year debt coverage analysis for AEST.MED.INT.HLD.SP.ADR/3. For market capitalisation and broader financial context, see how much is AEST.MED.INT.HLD.SP.ADR/3 worth.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.02x | €-12.23 Million | €554.12 Million | ▼ -113.2% |
| 2024 | 0.17x | €79.67 Million | €476.88 Million | ▲ +18.5% |
| 2023 | 0.14x | €74.29 Million | €527.03 Million | ▲ +226.1% |
| 2022 | -0.11x | €-75.13 Million | €672.25 Million | ▼ -267.0% |
| 2021 | 0.07x | €51.09 Million | €763.36 Million | — |